Fig. 4.
Fig. 4. Western analyses of the levels of cytosolic cyt c (A) and 116 kD 35S-labeled, in vitro-translated PARP or its cleaved products (B) in untreated and sphingosine (SO), sphinganine (SA), or C2 ceramide-treated HL-60/neo, HL-60/Bcr-Abl, and K562 cells. (C) Shows Western analysis of the cytosolic cyt c levels in HL-60/neo cells after exposure to SO, C2 ceramide, or zVAD alone; or zVAD plus SO or C2 ceramide (C) (see text).

Western analyses of the levels of cytosolic cyt c (A) and 116 kD 35S-labeled, in vitro-translated PARP or its cleaved products (B) in untreated and sphingosine (SO), sphinganine (SA), or C2 ceramide-treated HL-60/neo, HL-60/Bcr-Abl, and K562 cells. (C) Shows Western analysis of the cytosolic cyt c levels in HL-60/neo cells after exposure to SO, C2 ceramide, or zVAD alone; or zVAD plus SO or C2 ceramide (C) (see text).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal